ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag business disease medicine pharma biobusiness

Biotech Buys Autoimmune Firm for $7B
Kerry Grens | Jul 16, 2015 | 1 min read
Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.
The Growth of Iowa Biotech
Jenny Rood | Aug 1, 2016 | 7 min read
The state’s industry draws inspiration from medicine as well as agriculture.
computing a cure
Artificial Intelligence Shakes Up Drug Discovery
Bianca Nogrady | May 1, 2019 | 8 min read
The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.
The Profits of Nonprofit
Megan Scudellari | Jan 1, 2011 | 7 min read
The surprising results when drug development and altruism collide
Pharma Looks to Outer Space to Boost Drug R&D
Katarina Zimmer | Dec 1, 2020 | 9 min read
There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen.
Pharma’s Ghost Labs Find New Life
Katarina Zimmer | Nov 1, 2019 | 9 min read
Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.
How the Pharma Industry Pulled Off the Pivot to COVID-19
Diana Kwon | Jul 13, 2020 | 9 min read
The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.
Biopharma Looks to the Netherlands as European Hub
Jef Akst | Feb 1, 2021 | 7 min read
The recent move of the European Medicines Agency from London to Amsterdam is a reflection of the city’s vibrant life sciences and health sector and supporting industries.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Accessing Drugs for Medical Aid-in-Dying
Catherine Offord | Aug 16, 2017 | 9 min read
A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.

Run a Search

ADVERTISEMENT